|Author||: Michael Lim,Christopher Jackson|
|Publisher||: Academic Press|
|Release Date||: 2020-07-01|
|ISBN 10||: 0128197560|
|Pages||: 250 pages|
Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward. The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics. This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma. Summarizes the work in immunotherapy for glioma to-date, including the available evidence from preclinical studies and clinical trials Reviews the challenges and successes of the most promising strategies for brain tumor immunotherapy Provides a foundation for considering novel and combination therapies moving forward
Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunotherapy, immunosuppression, CAR therapy of brain tumors, and dendritic cell therapy for brain tumors. Very few agents have been shown to be efficacious in the treatment of malignant gliomas. Recently, there have been a number of studies demonstrating the potential success of immunotherapy for brain tumors. Immunotherapeutics are becoming the most frequent drugs to be used in cancer therapy. These new breakthroughs, now approved by the FDA, are a part of multiple phase III international trials and ongoing research in malignant glioma, meaning that the information in this cutting-edge book will be of great importance to practitioners and researchers alike. Comprehensive overview, providing an update on immunology, translational immunotherapy, and clinical trials relating to malignant gliomas Edited by a prominent neurosurgeon with contributions by leading researchers in the field Ideal resource for researchers and practitioners interested in learning about mechanisms that use the immune system to treat brain tumors
|Author||: Isaac Yang,Seunggu J. Han|
|Publisher||: Elsevier Health Sciences|
|Release Date||: 2012-07-15|
|ISBN 10||: 1455747688|
|Pages||: 240 pages|
Standard therapy for high grade glioma is a topic that is evolving, timely, and relevant. Guest Editors Isaac Yang, MD and Seunggu Han, MD have assembled a group of experts on management of high grade glioma. Some of the articles in this issue include: Use of language mapping to aid resection of eloquent gliomas; Clinical trials with immunotherapy; Clinical trials for small molecule inhibitors; Nanotechnology potential applications for GBM therapy; High Grade Gliomas in children; Modern Advances in Brain Tumor Treatments; Molecular pathways of Avastin interactions for the treatment of glioblastoma; and Quality of Life and Outcomes in Glioblastoma management.
An authoritative panel of researchers and clinicians critically reviews the entire field to provide a comprehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the field. Topics range from adoptive cellular and antibody-mediated immunotherapy of brain tumors to tumor vaccines and related strategies, and include many vanguard experimental strategies and immunological techniques for studying brain tumor immunotherapy. Cutting-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics.
|Author||: M.F. Chernov,Y. Muragaki,S. Kesari,I.E. McCutcheon|
|Publisher||: Karger Medical and Scientific Publishers|
|Release Date||: 2018-07-10|
|ISBN 10||: 3318060631|
|Pages||: 222 pages|
At present most intracranial gliomas are considered incurable with current treatment strategies, and the search for new modalities that may effectively control tumor growth continues. The chapters in this volume describe basic principles and therapeutic possibilities of several innovative techniques, including photodynamic therapy, laser-induced interstitial thermotherapy, stereotactic cryodestruction, high-intensity focused ultrasound ablation, boron neutron capture therapy, proton and carbon ion irradiation, targeted therapy, immunotherapy, gene therapy, local chemotherapy, and alternating electric fields therapy. Potential applications of extracellular vesicles and nanotechnology for management of gliomas are highlighted as well. Many of these methods have already demonstrated antitumor efficacy in clinical testing, whereas others are still under development. The materials presented in this book are mainly directed at clinicians treating patients with brain tumors, as well as clinical and basic researchers working in the field of neuro-oncology.
|Author||: Isaac Yang,Michael J Lim|
|Publisher||: Elsevier Health Sciences|
|Release Date||: 2010-01-05|
|ISBN 10||: 1455700452|
|Pages||: 229 pages|
For this issue, Dr. Michael Lim of Johns Hopkins and Dr. Isaac Yang of UCSF team up to deliver a packed issue on the latest developments in Immunotherapy. The issue covers hot topics such as immunostimulants, Passive Antibody Mediated Immunotherapy, Clinical Applications of A Peptide Based Vaccine, Challenges for Clinical Design of Immunotherapy Trials, The EGFRv3 Peptide Vaccine, Stem Cell Therapy and Dendritic Cell Vaccines, Dendritic Glioma Fusion Vaccine, Adoptive Cellular Immunotherapy, Virus Mediated Immunotherapy, and so much more.
Provides a summary of glioma biology, genetics and management, based on the world-leading Duke University Preston Robert Tisch Brain Tumor Center program.
Researchers’ knowledge of gliomas continues to advance rapidly at both the basic and translational levels, and Gliomas provides a thorough overview of the evolving fields of tumor biology and clinical medicine as they relate to our understanding of brain tumors. Gliomas reviews the current paradigms that underlie these fields, beginning with the molecular epidemiology of glioma susceptibility and prognosis through population-based science and genome-wide association studies. The book’s discussion of imaging modalities extends beyond advances in anatomical imaging to include metabolic and physiological studies. This work provides thorough discussion of the clinical view of tumors, ranging from the presentation of the patient to surgical management, and covers all therapeutic options for patient care, including chemotherapy, targeted molecular therapies, immunotherapies, and even personalized approaches to impact the set of lesions. Additionally, the book discusses radiotherapy with regard to the many options available to treat patients using myriad fractionated techniques with various sources. Finally, Gliomas reviews issues specific to the quality of life for patients, and techniques for maximizing the effect of caregivers. Edited and authored by premier researchers from around the world, Gliomas is a comprehensive reference for clinicians and researchers seeking the most up-to-date information on gliomas, and a guide to the best ways to effectively manage glioma patients and their care. Synthesizes widely dispersed information on the management of gliomas into one comprehensive resource Chapters written by international authors who are preeminent researchers in the field Fully explores the therapeutic options for patient care, from chemotherapy to radiotherapy to personalized approaches
Radiation Medicine Rounds is a trinary, hard cover periodical designed to provide an up-to-date review of a dedicated radiation medicine topic of interest to clinicians and scientists who are involved in the care of patients receiving radiotherapy. It is intended to serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinicians, medical physicists, cancer biologists, radiobiologists, and interdisciplinary colleagues throughout the oncology spectrum. This issue of Radiation Medicine Rounds discusses the more salient topics surrounding the role of radiation therapy for malignant gliomas. The specialty of radiation therapy has increased in complexity over the years, yet as technology improves, the goal of improving outcomes while decreasing toxicity remains critical. Malignant gliomas remain among the most devastating of all malignancies, yet as conventional treatments (surgery, radiation, and chemotherapy) have become optimized overall survival has improved. The underlying molecular and genetic mechanisms of these tumors are becoming better understood, with one of the most important realizations being that histopathologically identical malignant gliomas often demonstrate very distinct clinical behaviors. Malignant Gliomas provides the practitioner with a current overview of best practices, recent research, and future directions in the management of this complex and challenging cancer.
|Author||: Herbert B. Newton|
|Publisher||: Academic Press|
|Release Date||: 2018-03-28|
|ISBN 10||: 0128121017|
|Pages||: 848 pages|
Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Second Edition, provides a comprehensive overview of the molecular methodologies in the neuro-oncology field. There have been profound changes in the landscape of approaches to brain tumor therapy since the first edition—mainly in the areas of molecular biology and molecular therapeutics, as well as in the maturation of immunotherapy approaches (e.g., vaccines). This updated edition has a new, primary focus on multidisciplinary molecular methods, and is broadened to include the latest cutting-edge molecular biology, therapeutics, immunobiology and immunotherapy approaches. As the first comprehensive book to address the molecular research into these concepts, users will find it to be an invaluable resource on the topics discussed. Provides the most up-to-date information regarding conventional forms of cytotoxic chemotherapy, as well as the basic science and clinical application of molecular therapeutics for the treatment of brain tumors Broadly appeals to anyone interested in neuro-oncology and the treatment of brain tumors Features updated chapters on molecular biology, molecular therapeutics, maturation of immunotherapy approaches, and a focus on multidisciplinary molecular methods Includes a new section on the basic science of immunology, as well as thorough updates on the use of vaccine technology and immunotherapy for the treatment of brain tumors
|Author||: Moneeb Ehtesham|
|Release Date||: 2015-04-20|
|ISBN 10||: 3319165372|
|Pages||: 190 pages|
This volume presents the most current reviews on how cancer stem cells (CSCs) hypothesis dictates that the continued proliferation of a tumor is dependent on a sub-population of self-renewing and asymmetrically dividing neoplastic stem cells that supply a largely differentiated tumor. This volume provides a comprehensive overview of the characteristics of CSCs, their role in central nervous system (CNS) tumors, and the recent CSC-specific treatment modalities being used. The emerging focus on CSCs in brain tumors represents a paradigm shift in our understanding of the pathogenesis of these neoplasms. Importantly, the realization that a distinct sub-population of cells contributes disproportionately to the growth and sustenance of central nervous system tumors has important implications for the treatment of such tumors. To treat CNS tumors, there is now a growing need to treat CSCs to achieve adequate tumor control.
|Author||: Terry Lichtor|
|Publisher||: BoD – Books on Demand|
|Release Date||: 2015-03-25|
|ISBN 10||: 953512031X|
|Pages||: 434 pages|
A dramatic increase in knowledge regarding the molecular biology of brain tumors has been established over the past few years. In particular, recent new avenues regarding the role of microRNAs along with further understanding of the importance of angiogenesis, immunotherapy and explanations for the resistance of the tumors to radiation therapy have been developed. A discussion of certain surgical management issues including improvements in imaging along with issues concerning tumor induced epilepsy is included. It is hopeful that this new information will lead to efficacious treatment strategies for these tumors which remain a challenge. In this book, a review of the latest information on these topics along with a variety of new therapeutic treatment strategies with an emphasis on molecular targeted therapies is provided.
Treatment of glioma is currently one of the most challenging problems in oncology, as well as in neurosurgery. Despite major advances in our understanding of the pathomechanism, diagnosis by imaging and the availability of powerful therapeutic tools, the life expectancy of patients with glioblastoma has only been slightly prolonged and a cure remains elusive. None of the currently available surgical tools, including operative microscopes, lasers and image-guided surgery, can enable the detection and removal of all of the tumor tissue. In recent years, however, the landscape has been changing immeasurably, and molecular studies over the past two decades have identified a variety of genetic aberrations that are specifically associated with individual types of gliomas. In addition, certain molecular abnormalities have been linked to therapy responses, thereby establishing clinical biomarkers and molecular targets, and the use of novel agents is being investigated. These agents have been specifically engineered to exert specific cytotoxicity against gliomas, either on their own as single agents or in combination with other modalities. Moreover, there has been an enormous surge of interest in the area of immunology and immunotherapy, which has been facilitated by our understanding of the molecular basis of gliomas. Although several kinds of immunotherapeutic trials have been undertaken, we still await a great breakthrough in terms of clinical efficacy to prolong the survival time of glioma patients.
We all know that the field of neuro-oncology is heterogeneous and under continuous development with the addition of new knowledge and information on a regular basis. The present book "Brain Tumor - An Update" is an attempt to share the personal experiences of experts who are involved in neuro-oncology-related research. Through this book, the authors share their experiences and provide details about the pathophysiology, neuroimaging approaches, and management options, and how to go about decision-making in patients with brain tumors. We hope that the valuable contributions from the authors shall facilitate understanding about brain tumors. I am grateful to all the authors who have contributed their tremendous expertise, and I would like to acknowledge the outstanding support of Ms. Danijela Sakic, Author Service Manager, IntechOpen Science, who collaborated tirelessly in crafting this book.
|Author||: Michael E. Sughrue,Isaac Yang|
|Publisher||: Academic Press|
|Release Date||: 2019-08-03|
|ISBN 10||: 0128136340|
|Pages||: 256 pages|
New Techniques for Management of 'Inoperable' Gliomas radically challenges the assumption that certain gliomas cannot be removed with modern techniques, contesting stereotypical thinking and establishing new paradigms in the field. Gliomas are primary brain tumors which are often fatal. Recent data has demonstrated that despite the fact that surgery cannot cure gliomas, patient survival is substantially improved by removing as much of the tumor as possible. This fact has raised the imperative that neurologists try to improve techniques to bring surgical resection to as many patients as possible. This book brings new insights and technologies to the forefront, giving hope to patients. Provides the first comprehensive book to discuss techniques for removing gliomas that are traditionally deemed ‘inoperable’ Presents a great reference tool that challenges stereotypical thinking by offering techniques by innovative surgeons Includes chapters that are organized by different glioma types and surgery/techniques
The book contains the information of various aspects of newer developments and recent advances in the field of central nervous system (CNS) tumor molecular biology, tumor progression, clinical presentation, imaging and management. The authors from different reputed institutions shared their knowledge on this open access platform to disseminate their knowledge at global level. As it is obvious in the current text, the field of neurooncology is heterogeneous and under continuous development with addition of new knowledge and information on regular basis. The collective contributions from experts attempt to provide updates regarding ongoing research and developments pertaining to CNS tumor genetics and molecular aspects and their applied aspect in reference to patient management.
Meet the increasing need for effective brain tumor management with the highly anticipated revision of Brain Tumors by Drs. Andrew H. Kaye and Edward R. Laws. Over the past decade, enormous advances have been made in both the diagnosis and the surgical and radiotherapeutic management of brain tumors. This new edition guides you through the latest developments in the field, including hot topics like malignant gliomas, functional brain mapping, neurogenetics and the molecular biology of brain tumors, and biologic and gene therapy. Benefit from the knowledge and experience of Drs. Andrew H. Kaye and Edward R. Laws, globally recognized experts in the field of neurosurgery, as well as many other world authorities.
|Author||: Natasha J. Olby|
|Publisher||: Elsevier Health Sciences|
|Release Date||: 2014-11-12|
|ISBN 10||: 0323326919|
|Pages||: 273 pages|
This issue highlights the advances in neurological treatments for dogs and cats. Articles include: New Treatment Modalities for Brain Tumors in Dogs and Cats, Altered Mental Status in Dogs and Cats: Stupor and Coma, Steroid Use in Veterinary Neurology, Hereditary Ataxia and Paroxysmal Movement Disorders in Dogs and Cats, Paroxysmal Movement Disorders in Dogs and Cats, Cluster Seizures and Status Epilepticus, Aging in the canine and feline brain, Acute Spinal Cord Injury: Tetraparesis and Paraparesis, Meningoencephalitis of Unknown Etiology, and more!
This is truly an exciting time in the field of neuro-oncology, particularly in the area of hi- grade gliomas. The management of patients with high-grade gliomas has historically been one of the most challenging and disheartening fields in medicine, where failure is the rule and longevity is the exception. The jaded often state that despite purported advances in surgical and radiotherapeutic techniques and a myriad of clinical trials of medical therapies, the s- vival statistics for glioblastoma have not changed in the last three decades. The nihilism associated with these tumors is such that some practitioners still advise against treatment or even biopsy, recommending palliative care with the diagnosis based only on history and an MRI scan. If the current state-of-the-art in the diagnosis and management of high-grade gliomas was truly so bleak, there would be no reason to compile and publish a monograph on the subject. The fact is that we have recently entered an era where real progress is being made in our understanding and treatment of high-grade gliomas that is directly benefiting some patients. We are slowly but surely chipping away at this problem. One approach has exploited correlations between particular molecular markers and therapeutic response. The first such “breakthrough” in high-grade glioma was the observation that loss of chromosomes 1p and 19q uniformly predict chemosensitivity in anaplastic oligodendrogliomas (1).
Considered one of the most devastating and frightening of all cancers, cancers of the central nervous system (CNS) attack the complex organs that control not only the CNS but also the peripheral nervous system and many of the voluntary and involuntary body systems, with 20% to 40% of CNS cancers metastasizing to the brain. Site-Specific Cancer Series: Central Nervous System Cancers, a new volume in the Series edited by Deborah Hutchinson Allen and Laurie L. Rice, details the cancers of the brain and spinal cord. Chapters examine issues such as anatomy and physiology of the brain and spine, patient assessment, pathology, histology, and molecular markers of primary brain tumors, and adult and pediatric cancers of the brain and spinal cord. Other issues include treatment modalities (surgical treatments, chemotherapy, and radiotherapy), as well as pediatric therapeutic modalities, symptom management and psychological issues, and the current state of evidence-based practice. You can use this new volume as a guide to treating your patients and to providing sensitive and realistic care that optimizes the quality of life and permits a sense of hopefulness to prevail when many patients with type of cancer feel only pain and fear.